Earnings Preview - Cubist Pharmaceuticals, Inc. (CBST)
By:NewsyStocks   Wednesday, January 18, 2022 11:32 AM

Cubist Pharmaceuticals is expected to report earnings on Jan 19th.

In the last four quarters ended Sep 2011, the company's reported quarterly EPS exceeded analysts' consensus estimates. None raised and none lowered their forecast for the fiscal quarter ending December 2011.

I think, for the fourth quarter of 2011 (December 2011), the company is likely to report revenues of $210.3 million, an increase of 30 percent over the same quarter a year ago. The increase in revenue is attributable to the strong growth of CUBICIN, and the significant leverage in the company's business model. US CUBICIN full year 2011 net product revenues of $698.8 million were up 17 percent over 2010, while total CUBICIN full year 2011 net product revenues of $735.5 million were up 18 percent over 2010.

Service revenue and other revenue combined could come at $6 million in the quarter ended December 2011. Total costs and expenses are likely to increase by 22.5 percent. Net on net, the company is likely to report EPS of $0.32, compared to $0.24 in the same quarter in the previous fiscal year. Last month, the company said that it completed the acquisition of Adolor Corp. for an aggregate upfront cash consideration of about $221 million. All outstanding shares of Adolor were acquired for $4.25 per share in upfront cash plus one Contingent Payment Right (CPR) per share, entitling the holder to receive additional cash payments of up to $4.50 for each share owned if certain regulatory approvals and/or commercialization milestones for ADL5945 are achieved. The acquisition allows the company to begin marketing ENTEREG alongside CUBICIN and DIFICID, while continuing the development of ADL5945 together with our other promising late-stage candidates.